Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      Amsterdam UMC - Amsterdam University Medical Center; University of Amsterdam Amsterdam = Universiteit van Amsterdam (UvA); Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Centre de recherche en épidémiologie et santé des populations (CESP); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Hôpital Paul Brousse; Göteborgs Universitet = University of Gothenburg (GU); Laboratorio Farmaceutico CT San Remo, Italy (LFCT); Università degli Studi di Ferrara = University of Ferrara (UniFE); Université Grenoble Alpes (UGA); IRCCS Ospedale San Raffaele Milan, Italy; Università degli Studi di Milano = University of Milan (UNIMI); Amsterdam School of Public Health the Netherlands; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Universitat de Barcelona (UB); University of Vienna Vienna; University of Pisa - Università di Pisa; Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Casa Sollievo della Sofferenza San Giovanni Rotondo (IRCCS); Imperial College London; Centre Hospitalier Universitaire de Nancy (CHU Nancy); Centre Hospitalier Universitaire de Nîmes (CHU Nîmes); Université de Montpellier (UM); D&A Pharma Paris - Laboratoires pharmaceutiques (DAPP); Centre for Addiction and Mental Health Toronto (CAMH); University of Toronto; Technische Universität Dresden = Dresden University of Technology (TU Dresden); I.M. Sechenov First Moscow State Medical University Moscow, Russia (MSMU); Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS); Centro di Riferimento Alcologico della Regione Lazio Roma, Italy (CRARL); Bruno Scherrer Conseil Saint Arnoult en Yvelines (BSC); Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD); Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM); Hôpital Sainte-Marguerite CHU - APHM (Hôpitaux Sud ); Medizinische Universität Wien = Medical University of Vienna; Addiction Treatment Center ASL Biella, Italy (ATC - Local Health Unit); Universität Heidelberg Heidelberg = Heidelberg University; Barone Lombardo Hospital Canicattì, Italy (BLH); Amsterdam University Medical Centers (Amsterdam UMC)
    • بيانات النشر:
      HAL CCSD
      SAGE Publications
    • الموضوع:
      2022
    • Collection:
      Aix-Marseille Université: HAL
    • نبذة مختصرة :
      International audience ; Background: Sodium oxybate (SMO) has been shown to be effective in the maintenance of abstinence (MoA) in alcohol-dependent patients in a series of small randomized controlled trials (RCTs). These results needed to be confirmed by a large trial investigating the treatment effect and its sustainability after medication discontinuation. Aims: To confirm the SMO effect on (sustained) MoA in detoxified alcohol-dependent patients. Methods: Large double-blind, randomized, placebo-controlled trial in detoxified adult alcohol-dependent outpatients (80% men) from 11 sites in four European countries. Patients were randomized to 6 months SMO (3.3–3.9 g/day) or placebo followed by a 6-month medication-free period. Primary outcome was the cumulative abstinence duration (CAD) during the 6-month treatment period defined as the number of days with no alcohol use. Secondary outcomes included CAD during the 12-month study period. Results: Of the 314 alcohol-dependent patients randomized, 154 received SMO and 160 received placebo. Based on the pre-specified fixed-effect two-way analysis of variance including the treatment-by-site interaction, SMO showed efficacy in CAD during the 6-month treatment period: mean difference +43.1 days, 95% confidence interval (17.6–68.5; p = 0.001). Since significant heterogeneity of effect across sites and unequal sample sizes among sites ( n = 3–66) were identified, a site-level random meta-analysis was performed with results supporting the pre-specified analysis: mean difference +32.4 days, p = 0.014. The SMO effect was sustained during the medication-free follow-up period. SMO was well-tolerated. Conclusions: Results of this large RCT in alcohol-dependent patients demonstrated a significant and clinically relevant sustained effect of SMO on CAD. Trial registration: ClinicalTrials.gov Identifier: NCT04648423
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/35796481; inserm-04057658; https://inserm.hal.science/inserm-04057658; https://inserm.hal.science/inserm-04057658/document; https://inserm.hal.science/inserm-04057658/file/02698811221104063.pdf; PUBMED: 35796481; PUBMEDCENTRAL: PMC9548946; WOS: 000821650500001
    • الرقم المعرف:
      10.1177/02698811221104063
    • Rights:
      http://creativecommons.org/licenses/by/ ; info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.CEAF220E